Multiple Sclerosis
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
No minimum to 17 Years
Inclusion criteria
Inclusion criteria: Patients 1. Age under 18 years 2. Auto-immune mediated, demyelinating disorder of the CNS 3. No other suspected disease causing demyelination in the CNS 4. Written informed consent is obtained of parents or caregivers. In case the patient is 12 years of age or older, the patient needs to provide written informed consent as well. , Healthy controls 1. Age under 18 years 2. No known systemic auto-immune disease 3. Full siblings (same father and same mother) of the patient are eligible and not blood-related children sharing similar environments (school, neighbourhood etc). 4. Written informed consent is obtained , Other neurological diseases (OND): Patients will be included at the outpatient clinics of pediatric neurologists at Erasmus MC-Sophia. 1. Age under 18 years 2. No systemic auto-immune disease that might cause inflammatory disease in the CNS 3. Written informed consent is obtained of parents or caregivers. In case the child is 12 years of age or older, the child needs to provide written informed consent as well.
Exclusion criteria
Exclusion criteria: 1) Age of onset above 18 years 2) Inflammation in the CNS by other causes than ADS (for example systemic lupus erythematosus, Sj*gren syndrome, sarcoidosis,). 3) If written informed consent is not obtained. 4) Withdrawal from study by patient and/or parents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Identifying prognostic factors for disease course and severity - Identification of specific ADS subgroups - Role of environmental and genetic factors in MS and other ADS - Estimating incidence and prevalence of ADS subtypes in the Netherlands. - Accurate and suitable parameters expressing disease severity for pediatric ADS | — |
Countries
Netherlands
Outcome results
None listed